EUVIMEDEUVIMED entdecken
Crossref

Bioética de intervenção e o caso das drogas Bevacizumabe e Ranibizumabe para doenças da retina

Flávio R. L. Paranhos

Revista Iberoamericana de Bioética · 2016

DOI: 10.14422/rib.i02.y2016.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista Iberoamericana de Bioética, 2016. Verfasst von Flávio R. L. Paranhos.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

From the year 2000, on a class of biological drugs, the anti-VEGF proved to be quite effective in the treatment of retinal diseases, which have in its pathophysiological mechanism an important vascular proliferation component that can lead to blindness. Two of these drugs, bevacizumab and ranibizumab, are quite similar and have the same efficacy and safety. They were developed by the same laboratory and are commercialized by two major pharmaceutical companies through an agreement made between them. However, there is a big difference in the price of the drugs. The aim of this article is to present the Bioethics of intervention as grounds for choosing the cheaper drug, even if forced to do so by regulatory entities.

Zitieren

APA

Paranhos, F. R. L. (2016). Bioética de intervenção e o caso das drogas Bevacizumabe e Ranibizumabe para doenças da retina. Revista Iberoamericana de Bioética. https://doi.org/10.14422/rib.i02.y2016.004

Vancouver

Paranhos FRL. Bioética de intervenção e o caso das drogas Bevacizumabe e Ranibizumabe para doenças da retina. Revista Iberoamericana de Bioética. 2016. doi:10.14422/rib.i02.y2016.004

BibTeX
@article{Paranhos2016,
  author = {Paranhos, Flávio R. L.},
  title = {Bioética de intervenção e o caso das drogas Bevacizumabe e Ranibizumabe para doenças da retina},
  journal = {Revista Iberoamericana de Bioética},
  year = {2016},
  doi = {10.14422/rib.i02.y2016.004}
}
Kostenlos starten →